Physician profile
John A Eckman
NPI 1083774327
$11,753.05
in general payments reported to CMS, 2019-2025
29 companies · $756 in 2025
The $756 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,560 · 2020: $2,308 · 2021: $547 · 2022: $800 · 2023: $458 · 2024: $324 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492 · Consulting Fee: $31.15 · Education: $14.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.73 |
| Consulting Fee | $31.15 |
| Education | $14.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,838.43 | 2019-2025 | |
| Genentech USA, INC. | $1,946.26 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $784.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $578.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $463.53 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $449.89 | 2019-2025 | Airsupra |
| Csl Behring | $274.36 | 2019-2025 | Haegarda, Andembry |
| Covis Pharma Gmbh | $204.17 | 2019-2022 | |
| Pfizer INC. | $171.69 | 2019-2024 | |
| Optinose US, INC. | $149.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.01 | 2020-2022 | |
| Organon LLC | $85.59 | 2025 | Vtama |
| Grifols USA, LLC | $85.50 | 2019-2023 | Prolastin-C Liquid |
| Alk-Abello, INC | $76.76 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.63 | 2019-2024 | Spiriva Respimat |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $69.67 | 2019-2023 | Airduo Digihaler |
| Kaleo, INC. | $56.69 | 2020-2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $41.30 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $34.15 | 2021-2023 | Orladeyo |
| Blueprint Medicines Corporation | $32.70 | 2024-2025 | Ayvakit |
| Adma Biomanufacturing LLC | $31.15 | 2024-2025 | |
| Lilly USA, LLC | $27.27 | 2025 | Ebglyss |
| Greer Laboratories, INC. | $24.04 | 2025 | Oralair |
| Dermavant Sciences, INC. | $18.91 | 2024 | Vtama |
| Sanofi Pasteur INC. | $18.32 | 2023 | |
| Leo Pharma INC. | $18.18 | 2022 | |
| Cycle Pharmaceuticals INC | $17.48 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $17.47 | 2025 | Ryaltris |
| Abbvie INC. | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.